Body weight reductions in the dapagliflozin group were
maintained during the extension periods, and were consistent
with glycosuria and associated calorie loss. Weight gain in the
glipizide group corresponded to its mechanism of action, with
increased insulin release, leading to increased cellular glucose
uptake